Imagine a parent sitting in my office, holding a stack of medical records and facing a diagnosis so rare, most doctors never see it in their entire careers. Their child has an “ultra-rare” disease—one that might only affect a handful of people worldwide. The story is all too real. For decades, families in this situation have felt isolated, overlooked, and desperate for answers. The FDA (U.S. Food and Drug Administration) is now responding to this urgent need in a very new way: by supporting the development of “individualized therapies”—treatments crafted for just one patient, or a tiny group, based specifically on their unique genetic makeup. This blog post explores what this shift means, how it’s unfolding, and why it could change the future of medicine for ultra-rare disease patients everywhere.

Ultra-rare diseases are conditions so uncommon that drug companies haven’t traditionally invested in finding treatments—often because there are fewer than a few hundred, or even just a handful, of known cases worldwide. This used to mean the odds of a breakthrough were slim. But advances in genetic medicine, diagnostics, and personalized drug development are opening new doors. Let’s walk through what “individualized therapy” really means, why the FDA is now open to these one-of-a-kind approaches, and some hard truths, hopes, and realities for families facing ultra-rare diagnoses.

What Are Ultra-Rare Diseases—and Why Do They Matter?

An ultra-rare disease is generally defined as a condition that affects fewer than 1 in 50,000 people. Sometimes we’re talking about disorders so rare, they might be found in just a single child, or a couple dozen people worldwide. Classic examples include certain metabolic conditions, rare genetic mutations, and previously unknown syndromes. Altogether, more than 7,000 rare diseases have been identified, though most remain without a cure—or even an effective treatment.

Why does this group matter? Because if you add up all rare diseases, they impact millions of people collectively. About 1 in 10 Americans lives with a rare disease, according to the National Institutes of Health (NIH). For those with ultra-rare forms, there are unique challenges: virtually no clinical research, very limited understanding by most doctors, and little or no interest from big pharmaceutical companies—at least historically. These families are left to navigate a complex and frustrating world, often fundraising on their own and seeking out academic researchers willing to help.

In the exam room, here’s the scenario I hear time and again: A child is born with unusual symptoms, specialists eventually identify the culprit—a genetic typo no one else has seen. The diagnosis feels like both an answer and a dead end. Families quickly learn there is no “standard” treatment, and every path forward feels experimental.

How Is the FDA Approaching “Individualized Therapies”?

The FDA is best known for its extensive drug approval process—requiring large studies, safety checks, and years of review. This system works when a new therapy might help tens of thousands of people. But what about when a disease only affects one child? The traditional system simply doesn’t fit. That’s where the interest in individualized therapies comes in.

So what is an individualized therapy? Most often, it’s a treatment designed specifically for a single patient’s genetic mutation—sometimes called a “n=1” therapy. This might involve a custom gene therapy, antisense oligonucleotide (a kind of highly targeted genetic medication), or another precision medicine approach. These are not just “niche” drugs—they are built for the individual, using that person’s genetic information as a blueprint.

In recent years, the FDA has signaled it wants to encourage this innovation, while still protecting patients. In 2022 and 2023, the agency issued new frameworks and guidance documents for gene therapy and individualized antisense therapies for ultra-rare diseases. The FDA’s approach: Offer flexible, “case-by-case” oversight, with less rigid requirements, recognizing that a single patient’s improvement can still be meaningful evidence. The agency still reviews safety and effectiveness, but works more directly with clinicians and families through “expanded access” or “compassionate use” programs. This is a big change from the one-size-fits-all drug approval model of the past.

Let me explain with a brief example: In 2019, a young girl named Mila was the first person to receive a custom DNA-based treatment (“Milasen”) for her ultra-rare Batten disease mutation. Academic researchers and the FDA worked with Mila’s family to approve a therapy designed just for her. Mila’s treatment would never have advanced under traditional drug development standards—but the rapid, collaborative approach gave her a fighting chance, while generating new knowledge that could eventually help others.

How Do Individualized Therapies Work in Practice?

Developing a personalized therapy is usually a collaboration between specialized researchers, clinicians, the patient’s family, and regulatory authorities. Here’s a simplified rundown:

First, the patient’s genetic mutation is identified through advanced DNA testing. Academic labs and biotech groups then analyze whether an existing therapy (or a modification of it) could target that mutation. Sometimes, entirely new genetic medicines are designed and created in the lab. After initial safety testing (often in cell models or animals), the FDA may grant special permission—outside of a typical clinical trial—for that unique therapy to be used by the patient. Doctors then monitor for both safety and benefit in real time, reporting back to the FDA and sometimes publishing the results for the medical community.

The costs and logistics can be staggering. Because each therapy is “custom-matched,” there’s no mass manufacturing and little chance of commercial return. Many families raise the hundreds of thousands needed through non-profit groups, grants, or crowdfunding. Insurance coverage for these one-off therapies is limited, though advocacy groups are pressuring for change.

In clinic, I’ve met families weighing whether to enroll in such “compassionate use” protocols. The risks are not small—the therapy may be unproven, and real side effects are possible. But for many, the hope outweighs the uncertainty. The clinical community, including groups like the NIH and major children’s hospitals, is working hard to ethically expand these options while keeping patient safety at the center.

What Kinds of Individualized Therapies Are Being Developed?

The most common types right now are genetic therapies called antisense oligonucleotides and certain gene therapies tailored to a person’s precise mutation. Let me break these down simply:

Antisense oligonucleotides (ASOs) are short, lab-crafted pieces of genetic code that can “block” or “fix” the faulty part of a gene’s message. If someone’s disease is caused by a spelling mistake in a gene, an ASO can sometimes override that mistake, restoring the normal protein or stopping the production of a harmful one. ASOs are delivered directly into the body (often by spinal injection) and can be custom designed based on the patient’s specific DNA change.

Gene replacement or gene editing therapies insert new genetic material or “fix” a mutation at its source. Some use harmless viruses to deliver the corrected gene to the right cells, while newer “gene editing” tools like CRISPR may directly repair a DNA typo. This is still challenging science and carries risks—but early results in some rare diseases are giving families hope.

There are also “repurposed” drugs, where a medication already approved for another condition is used off-label based on its potential to help an ultra-rare genetic mutation. This approach can sometimes speed things up, though it’s not as personalized as custom genetic therapies.

What Are the Benefits and Limitations of This Approach?

The biggest benefit is simple: hope. For the first time, families with ultra-rare diseases have a pathway—however experimental—to a tailored treatment. The old “there’s nothing we can do” answer is being replaced, at least occasionally, with a real scientific effort to help.

Another advantage: The science behind individualized therapies is advancing knowledge for everyone. What we learn on a tiny scale could shape future treatments for rare and even common conditions. Gene therapy breakthroughs first proven in rare diseases have led to broader research into conditions like sickle cell disease, hemophilia, and certain inherited blindness syndromes.

However, there are serious limitations and ethical questions. These treatments are still experimental, with unknown long-term risks. They’re expensive, and most patients cannot access them. The process is intensive, time-consuming, and usually out of reach for those without significant expertise, connections, and resources. There’s also a risk of false hope—science can’t always deliver, and not every gene can be safely “fixed.” The FDA, too, faces the challenge of encouraging innovation without sacrificing safety or fairness.

What Myths Exist Around Individualized Therapies?

It’s easy to read headlines about “custom cures” and picture medical miracles happening overnight. The reality is much more complex. One common myth is that gene therapies for ultra-rare diseases are “quick fixes.” In truth, developing, testing, and delivering a safe, effective drug—even for just one person—can take years, with no guarantee of success.

Another misconception is that “designer medicine” will rapidly become routine for all rare diseases. As of now, these efforts are still the exception, not the rule. For most rare and ultra-rare diseases, no tailored therapy exists, and families must still rely on best supportive care and symptom management. There’s a real risk that stories of rare success distract from the gritty, daily work needed to improve care for all patients, not just those with access to the latest science.

FAQs About the FDA and Individualized Therapies for Ultra-Rare Diseases

Can families request individualized therapies for their loved ones?

In many cases, yes, but it’s highly specialized. A patient’s clinical team—often academic researchers or experts in rare diseases—must submit proposals through “expanded access” or “compassionate use” channels. The FDA will consider the scientific evidence and patient need, but the process takes partnership and persistence. Not all requests are granted, and safety is paramount.

Does insurance cover these treatments?

Coverage is rare. Most individualized genetic therapies are experimental and not FDA-approved for broad use, so insurers generally don’t pay. In some cases, nonprofit groups, research grants, or family fundraising bridges the gap—but cost remains a major barrier.

How does the FDA balance access and safety?

The FDA walks a tightrope. On one hand, it wants to accelerate promising treatments for patients with no other options. On the other hand, it must make sure therapies don’t do more harm than good. The FDA asks for as much safety and scientific evidence as possible, and closely monitors patient progress—but it has developed more flexible pathways specifically for ultra-rare and individualized drugs.

Will this approach become the new norm for all rare diseases?

It's unlikely to become routine for most diseases soon, given the time, cost, and scientific limits involved. However, the lessons and frameworks being created now may pave the way for more “personalized” therapies, not only for ultra-rare diseases but for broader groups as science advances.

The Future: FDA, Individualized Therapies, and Hope for Ultra-Rare Diseases

Let’s return to that clinic room for a moment. The truth is: every advance in individualized therapy for ultra-rare diseases means everything to the families it touches. The stories of children like Mila don’t just make headlines—they shift the conversation about what’s possible when medicine meets compassion, innovation, and partnership. Each success lays a brick in the road toward broader access and better solutions for people who’ve long felt left out of the system.

As a physician, I’m encouraged by the FDA’s willingness to adapt, experiment, and learn with patients and families in these extraordinary situations. These therapies are not magic bullets, but they represent a powerful change: a system striving to meet people where they are, even if that means reinventing the rules. By focusing on science, transparency, and patient partnership, we’re slowly changing what the words “no treatment available” will mean in the years ahead.

Join Our Healthcare Community for Insights on Rare Diseases and Medical Innovation

If this topic personally touches your family or your curiosity, I invite you to subscribe to our newsletter. You’ll receive information on the newest breakthroughs for rare diseases, FDA updates, research trends, and stories of hope from families and experts navigating this frontier. As always, please remember that for personalized medical advice and treatment options, you should consult with your own healthcare provider. Thank you for joining me in exploring this vital and rapidly evolving area in medicine.